glp-1 nerve pain Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment Weight Loss Injections for Chronic

Looking Ahead As the market evolves, stakeholders are watching for regulatory updates and court decisions that could reshape the boundaries of compounding

Break Down Heavy Meals and Prevent Digestive Discomfort

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and tirzepatide (Mounjaro, Zepbound) have dramatically improved treatment options for Type 2 diabetes and obesity

In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

Please contact GSK Consumer Healthcare directly for more information

Explore the emerging research into semaglutide, tirzepatide, retatrutide and anhedonia.